Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CWBRNASDAQ:EVOKNASDAQ:KLTONYSE:PTN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCWBRCohBar$0.41$0.41$0.00▼$1.01$1.19M1.394,364 shsN/AEVOKEvoke Pharma$3.11-5.8%$2.85$1.94▼$12.32$4.64M0.16122,771 shs23,662 shsKLTOKlotho Neurosciences$0.16-10.5%$0.22$0.11▼$8.11$4.51M-1.1569,834 shs231,216 shsPTNPalatin Technologies$0.09-44.6%$0.00$0.09▼$2.48$2.45M0.942.28 million shs14.57 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCWBRCohBar0.00%0.00%0.00%0.00%-48.75%EVOKEvoke Pharma+6.80%+22.00%+46.67%-32.25%-41.49%KLTOKlotho Neurosciences+6.24%+6.24%+16.37%-49.83%+18,059,900.00%PTNPalatin Technologies-5.45%-17.07%+16,999,900.00%+16,999,900.00%+16,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCWBRCohBarN/AN/AN/AN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AN/AN/AN/AKLTOKlotho NeurosciencesN/AN/AN/AN/AN/AN/AN/AN/APTNPalatin TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCWBRCohBar 0.00N/AN/AN/AEVOKEvoke Pharma 0.00N/AN/AN/AKLTOKlotho Neurosciences 0.00N/AN/AN/APTNPalatin Technologies 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCWBRCohBarN/AN/AN/AN/A$5.27 per shareN/AEVOKEvoke Pharma$10.25M0.45N/AN/A($9.26) per share-0.34KLTOKlotho NeurosciencesN/AN/A$0.17 per share0.95($2.16) per shareN/APTNPalatin Technologies$350K6.99N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCWBRCohBar-$12.18MN/A0.00∞N/AN/AN/AN/AN/AEVOKEvoke Pharma-$7.79M-$4.40N/A∞N/A-71.32%-308.49%-53.66%5/13/2025 (Estimated)KLTOKlotho Neurosciences$1.35MN/A0.00∞N/AN/AN/A-25.89%N/APTNPalatin TechnologiesN/A-$1.55N/A∞N/AN/AN/AN/AN/ALatest CWBR, KLTO, PTN, and EVOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025EVOKEvoke Pharma-$0.33N/AN/AN/A$3.32 millionN/A3/31/2025Q4 2024KLTOKlotho NeurosciencesN/A-$0.07N/A-$0.07N/AN/A3/13/2025Q4 2024EVOKEvoke Pharma-$0.25-$0.49-$0.24-$0.49$3.08 million$3.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCWBRCohBarN/AN/AN/AN/AN/AEVOKEvoke PharmaN/AN/AN/AN/AN/AKLTOKlotho NeurosciencesN/AN/AN/AN/AN/APTNPalatin TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCWBRCohBarN/AN/AN/AEVOKEvoke PharmaN/A1.441.39KLTOKlotho NeurosciencesN/A0.160.16PTNPalatin TechnologiesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCWBRCohBar2.47%EVOKEvoke PharmaN/AKLTOKlotho Neurosciences20.07%PTNPalatin Technologies11.50%Insider OwnershipCompanyInsider OwnershipCWBRCohBar6.51%EVOKEvoke Pharma2.29%KLTOKlotho Neurosciences2.00%PTNPalatin Technologies7.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCWBRCohBar102.91 millionN/ANot OptionableEVOKEvoke Pharma41.49 million1.40 millionNot OptionableKLTOKlotho NeurosciencesN/A28.01 million26.54 millionN/APTNPalatin Technologies3026.01 millionN/AN/ACWBR, KLTO, PTN, and EVOK HeadlinesRecent News About These CompaniesPalatin Technologies Announces Encouraging Pre-Clinical Data Of PL9588 For Glaucoma TreatmentMay 7 at 8:05 PM | nasdaq.comPalatin Technologies faces delisting from NYSE American due to low stock priceMay 7 at 8:05 PM | in.investing.comPalatin Technologies faces delisting from NYSE American due to low stock priceMay 7 at 8:05 PM | in.investing.comNYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)May 7 at 5:20 PM | businesswire.comPalatin Expects $11.5 Million Financing to Cure NYSE American Delisting NoticeMay 7 at 8:15 AM | prnewswire.comPalatin Technologies Announces Pricing of up to $23 Million Public OfferingMay 7 at 8:00 AM | prnewswire.comStockNews.com Begins Coverage on Palatin Technologies (NYSE:PTN)May 6 at 1:17 AM | americanbankingnews.comPalatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma TherapyMay 5 at 7:30 AM | prnewswire.comPL9643 shows promise in dry eye disease treatmentApril 30, 2025 | investing.comPalatin Reports Positive Results From Responder Analyses Of Phase 3 MELODY-1 Study In DEDApril 30, 2025 | nasdaq.comPalatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye DiseaseApril 29, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCWBR, KLTO, PTN, and EVOK Company DescriptionsCohBar NASDAQ:CWBR$0.41 0.00 (0.00%) As of 01/23/2025CohBar, Inc., a clinical stage biotechnology company, develops mitochondria and peptides based therapeutics for the treatment of chronic and age-related diseases. It develops CB4211, a therapeutic that is in Phase 1a/1b clinical trial for the treatment of nonalcoholic steatohepatitis and obesity; and CB5138 Analogs, which is in preclinical study to treat idiopathic pulmonary fibrosis and other fibrotic diseases. CohBar, Inc. was incorporated in 2007 and is based in Menlo Park, California.Evoke Pharma NASDAQ:EVOK$3.11 -0.19 (-5.76%) Closing price 03:59 PM EasternExtended Trading$3.27 +0.16 (+5.02%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.Klotho Neurosciences NASDAQ:KLTO$0.16 -0.02 (-10.50%) As of 03:58 PM EasternKlotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.Palatin Technologies NYSE:PTN$0.09 -0.08 (-44.65%) As of 12:26 PM EasternPalatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
